Tanzania

In Tanzania, the largest country in East Africa, estimated life expectancy is 44 years and falling while the infant mortality rate is 99 per 1,000 and rising. Notably, Tanzania bears a large share of the global HIV/AIDS pandemic; according to the UNAIDS 2006 Report of the Global AIDS Epidemic, an estimated 1.4 million people (6.5% of adults) were living with HIV in 2005. These phenomenae are largely attributable to the national HIV/AIDS infection rate. USAID calculated that, without intervention, there will be approximately 1.8 million AIDS orphans in Tanzania by 2010. Tanzania is one of 15 US President's Emergency Plan Emergence Plan for AIDS Relief (PEPFAR) focus countries receiving support for comprehensive HIV/AIDS prevention, treatment and care programs. (read Tanzania report). According to a 2012 USAID-issued HIV/AIDS Health Profile for Tanzania, overall HIV prevalence among adults decreased from 7.1 percent in 2001 to 5.6 percent in 2009. Read full report.

CCGHE RESPONDS

CCGHE currently provides open access to several HIV-related distance learning continuing medical education programs such as Johns Hopkins Infectious Diseases Grand Rounds, which are recorded and archived. Health workers from Tanzania are also tuning into our bi-weekly HIV Clinical Case Discussions. CCGHE has future plans to develop distance education courses that specifically meet the needs of health care providers in Tanzania.

Studies/Projects
Publications

A5207: Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine

Post Date:

2004-12-20

Countries:

This study was terminated January 16, 2014; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional...

Prevalence of neurotoxicity symptoms among postpartum women on Isoniazid Preventive Therapy and Efavirenz-based treatment for HIV—An exploratory objective of the IMPAACT P1078 randomized trial

Post Date:

2022-06-21

Countries:

Publication:

BMC Pregnancy and Childbirth

Background This exploratory analysis investigates the prevalence and risk factors of neurocognitive toxicity in postpartum women on HIV treatment in response to a concern of an Isoniazid Preventive Therapy (IPT)/Efavirenz interaction. Trial Design Pregnant women on HIV treatment from countries with...

Isoniazid preventive therapy in HIV-infected pregnant and postpartum women

Post Date:

2019-10-03

Countries:

Clinical Sites:

Publication:

New England Journal of Medicine

New England Journal of Medicine: Dr. Amita Gupta and colleagues found that the current standard of care given to HIV+ pregnant women to prevent TB should wait until 12 weeks after delivery. The study underscores the need to include pregnant women in clinical trials.